Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts

Blood, Vol. 110, Issue 2, 651-660, July 15, 2007
This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells
Blood Rink et al. 110: 651

Supplemental materials for Rink et al, Vol 110, Issue 2, 651-660

Files in this Data Supplement:

  • Figure S1. Enhanced activation of the ATM kinase in BCR/ABL-positive leukemia cells (JPG, 43.8 KB) -
    BCR/ABL (B/A)-positive or parental (P) M07e cells were untreated or treated with MMC for 8 hours. (Upper panel) Activation of ATM was assessed in total cell lysates by SDS-PAGE followed by Western blotting using antibodies recognizing ATM phosphorylated on S1981 (upper box) and total ATM (lower box). DNA damage-dependent autophosphorylation of ATM on S1981 initiates its catalytic activity.1 (Lower panel) ATM kinase assay was performed according to Adamson et al.2 Briefly, ATM immunoprecipitates obtained from the indicated cells were used for the kinase reaction with the GST-p53 as a substrate. The reactions were resolved by SDS-PAGE and examined by Western blotting using antibodies recognizing p53 phosphoserine-15 (upper box) and GST (lower box).





  • Figure S2. Time-dependent enhancement of pNbs1 in CML-BC cells (JPG, 50 KB) -
    CD34+ cells were isolated from healthy donors (Normal) and CML-blast crisis (CML-BC) patients. Cells were treated with 0.5 µg/mL MMC for 0, 4, 8, and 12 hours in the absence of growth factors. pNbs1, Nbs1, Mre11, and Rad50 were detected by Western analysis.





  • Figure S3. Downregulation of Nbs1 in BCR/ABL-M07e cells decreased resistance to MMC (JPG, 52.8 KB) -
    M07e (P) and BCR/ABL-M07e (B/A) cells were transfected with siRNA specific for Nbs1 (siS) or nontargeting control siRNA, (siC). Ninety-six hours after electroporation, cells were plated in methylcellulose in the presence of GM-CSF and the indicated doses of MMC. Nbs1 and tubulin expression was examined via Western analysis to confirm Nbs1 downregulation. Colonies were counted after 7 days. Results represent the percent of colonies (± SD) in comparison to untreated group; P<0.01.





This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020